Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW: FE 999302 add-on to Follitropin Delta in COS
NCT03564509Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- May 2018
- Primary completion
- Oct 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of choriogonadotropin beta in infertility, sponsored by Ferring Pharmaceuticals. Primary endpoint: Number of good-quality blastocysts on Day 5 after oocyte retrieval. Started May 2018; status: completed.
02
Drugs
choriogonadotropin beta
03
Conditions
infertility
Beyond the preview
Go deeper on NCT03564509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564509.